An Insight into the Therapeutic Potential of Phytobioactives for Diabetic Neuropathy

Abstract

Diabetic neuropathy, a debilitating complication of diabetes, arises from chronic hyperglycemia-induced inflammation and oxidative stress, leading to progressive nerve damage. Current therapeutic strategies often focus on symptomatic relief rather than addressing the underlying pathophysiology. Emerging evidence highlights the therapeutic potential of phytobioactives with robust anti-inflammatory and antioxidant properties as promising alternatives for diabetic neuropathy management. Phytobioactives such as flavonoids, polyphenols, alkaloids, and terpenoids demonstrate significant potential by mitigating oxidative stress, inhibiting pro-inflammatory cytokines, and promoting neuroprotection. Furthermore, combination approaches utilizing the synergistic effects of these phytobioactives have shown enhanced efficacy in preclinical models, targeting multiple pathways involved in the progression of diabetic neuropathy. However, clinical translation is hindered by challenges including low bioavailability, chemical instability, and suboptimal dosage. This review explores the mechanistic roles, preclinical evidence, and clinical challenges of phytobioactives in diabetic neuropathy therapy, emphasizing the need for advanced formulation strategies and well-designed clinical trials to optimize their therapeutic potential. Leveraging these phytobioactives could pave the way for more effective and holistic diabetic neuropathy treatments.

Keywords

Diabetic neuropathy - phytobioactives - antioxidants - inflammation - oxidative stress - neuroprotection

Publikationsverlauf

Eingereicht: 30. Januar 2025

Angenommen nach Revision: 15. September 2025

Artikel online veröffentlicht:
17. Oktober 2025

• References

• 1 Pop-Busui R, Boulton AJ, Feldman EL. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2016; 40: 136
• 2 Ebbell B. The papyrus Ebers. Copenhagen and Oxford. Oxford University Press; 1937. 115.
• 3 Eknoyan G. A Historical Overview of Diabetic Nephropathy. In: Diabetic Nephropathy: Pathophysiology and Clinical Aspects. 2019: 3-19
• 4 Carmichael J, Fadavi H, Ishibashi F. et al. Advances in screening, early diagnosis and accurate staging of diabetic neuropathy. Front Endocrinol 2021; 12: 671257
• 5 Callaghan BC, Cheng HT, Stables CL. et al. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol 2012; 11: 521-534
• 6 Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012; 28: 8-14
• 7 Dyck PJ, Sinnreich M. Diabetic neuropathies. Continuum 2003; 9: 19-34
• 8 Sumner CJ, Sheth S, Griffin JW. et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-111
• 9 Brown MJ, Asbury AK. Diabetic neuropathy. Ann Neurol 1984; 15: 2-12
• 10 Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J 2006; 82: 95-100
• 11 Fatima K, Hussain Z, Hamid R. Oxidative stress and diabetic complication: A systematic review. Chemistry & Biology Interface. 2021 11. 182-196
• 12 Bierhaus A, Haslbeck KM, Humpert PM. et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Investig 2004; 114: 1741-1751
• 13 Vincent AM, Russell JW, Low P. et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612-628
• 14 Pop-Busui R, Boulton AJ, Sosenko JM. Peripheral and autonomic neuropathy in diabetes. In: Cowie CC, Casagrande SS, Menke A et al, eds. Diabetes in America. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018
• 15 Sivitz WI, Yorek MA. Mitochondrial dysfunction in diabetes: From molecular mechanisms to functional significance and therapeutic opportunities. Antioxid Redox Signal 2010; 12: 537-577
• 16 Wu MY, Yiang GT, Lai TT. et al. The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxid Med Cell Longev 2018; 2018: 3420187
• 17 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
• 18 Giugliano D, Ceriello A, Esposito K. Glucose metabolism and hyperglycemia. Am J Clin Nutr 2008; 87: 217S-222S
• 19 Sandireddy R, Yerra VG, Areti A. et al. Neuroinflammation and oxidative stress in diabetic neuropathy: Futuristic strategies based on these targets. Int J Endocrinol 2014; 2014: 674987
• 20 Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005; 54: 1615-1625
• 21 Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res 2014; 80: 21-35
• 22 Yerra VG, Negi G, Sharma SS. et al. Potential therapeutic effects of the simultaneous targeting of the Nrf2 and NF-κB pathways in diabetic neuropathy. Redox Biol 2013; 1: 394-397
• 23 King RH. The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol Pathol 2001; 54: 400
• 24 Wang CH, Wen MS, Cherng WJ. et al. Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. J Diabetes Investig 2020; 11: 110-124
• 25 Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep 2019; 19: 86
• 26 Hansen CS, Määttä LL, Andersen ST. et al. The epidemiology of diabetic neuropathy. In: Tesfaye S, Gibbons CH, Malik RA, Veves A, eds. Diabetic Neuropathy. Contemporary Diabetes. Cham: Humana; 2023.
• 27 Lamour J, Grimm D, Smith E. et al. Treating diabetic peripheral neuropathy using a novel, nanotechnology-based topical formulation to improve pain, sensitivity, and function. Int J Diabetes Clin Res 2021; 8: 149
• 28 Padhi S, Dash M, Behera A. Nanophytochemicals for the treatment of type II diabetes mellitus: A review. Environ Chem Lett 2021; 19: 4349-4373
• 29 Yuan W, Fukuda S, Inoue T. et al. Establishment of a diabetes mellitus type 1 model in the common marmoset. Sci Rep 2019; 9: 14546
• 30 Moisset X, Bouhassira D, Couturier JA. et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Revue Neurologique 2020; 176: 325-352
• 31 Alles SR, Cain SM, Snutch TP. Pregabalin as a pain therapeutic: Beyond calcium channels. Front Cell Neurosci 2020; 14: 83
• 32 Kremer M, Salvat E, Muller A. et al. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience 2016; 338: 183-206
• 33 Saleh DO, Sedik AA. Novel drugs affecting diabetic peripheral neuropathy. Iranian J Basic Med Sci 2024; 27: 657
• 34 Jali AM, Banji D, Banji OJ. et al. Navigating preclinical models and medications for peripheral neuropathy: A review. Pharmaceuticals 2024; 17: 1010
• 35 Riaz M, Khalid R, Afzal M. et al. Phytobioactive compounds as therapeutic agents for human diseases: A review. Food Sci Nutr 2023; 11: 2500-2529
• 36 Nam YH, Moon HW, Lee YR. et al. Panax ginseng (Korea Red Ginseng) repairs diabetic sensorineural damage through promotion of the nerve growth factor pathway in diabetic zebrafish. J Ginseng Res 2019; 43: 272-281
• 37 Røikjer J, Borbjerg MK, Andresen T. et al. Diabetic peripheral neuropathy: Emerging treatments of neuropathic pain and novel diagnostic methods. J Diabetes Sci Tech. 2024: 1-16 19322968241279553
• 38 Khursheed R, Singh SK, Wadhwa S. et al. Opening eyes to therapeutic perspectives of bioactive polyphenols and their nanoformulations against diabetic neuropathy and related complications. Expert Opin Drug Deliv 2021; 18: 427-448
• 39 Kabir MT, Tabassum N, Uddin MS. et al. Therapeutic potential of polyphenols in the management of diabetic neuropathy. Evid-Based Complementary Altern Med 2021; 2021: 9940169
• 40 Sood A, Kumar B, Singh SK. et al. Flavonoids as potential therapeutic agents for the management of diabetic neuropathy. Curr Pharm Des 2020; 26: 5468-5487
• 41 Superti F, Russo R. Alpha-lipoic acid: Biological mechanisms and health benefits. Antioxidants 2024; 13: 1228
• 42 Salehi B, Berkay Yılmaz Y, Antika G. et al. Insights on the use of α-lipoic acid for therapeutic purposes. Biomolecules 2019; 9: 356
• 43 Zhang BY, Zhang YL, Sun Q. et al. Alpha-lipoic acid downregulates TRPV1 receptor via NF-κB and attenuates neuropathic pain in rats with diabetes. CNS Neurosci Ther 2020; 26: 762-772
• 44 Zhang W, Xiao D, Mao Q. et al. Role of neuroinflammation in neurodegeneration development. Signal Transd Target Ther 2023; 8: 267
• 45 Giri PM, Banerjee A, Ghosal A. et al. Neuroinflammation in neurodegenerative disorders: Current knowledge and therapeutic implications. Int J Mol Sci 2024; 25: 3995
• 46 Kim T, Davis J, Zhang AJ. et al. Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells. Biochem Biophys Res Commun 2009; 388: 377-382
• 47 Seo KI, Choi MS, Jung UJ. et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008; 52: 995-1004
• 48 Ejaz A, Wu D, Kwan P. et al. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 2009; 139: 919-925
• 49 Biswas SK, McClure D, Jimenez LA. et al. Curcumin induces glutathione biosynthesis and inhibits NF-κB activation and interleukin-8 release in alveolar epithelial cells: Mechanism of free radical scavenging activity. Antioxid Redox Signal 2005; 7: 32-41
• 50 Liu Y, Liu F, Xing D. et al. Effects of cinnamon powder on glucose metabolism in diabetic mice and the molecular mechanisms. Foods 2023; 12: 3852
• 51 Chang W, Chen L, Hatch GM. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol 2015; 93: 479-486
• 52 Cao C, Su M. Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Exp Ther Med 2019; 17: 3009-3014
• 53 Alkhalaf MI, Hussein RH, Hamza A. Green synthesis of silver nanoparticles by Nigella sativa extract alleviates diabetic neuropathy through anti-inflammatory and antioxidant effects. Saudi J Biol Sci 2020; 27: 2410-2419
• 54 Omar N, Ismail CA, Long I. Tannins in the treatment of diabetic neuropathic pain: Research progress and future challenges. Front Pharmacol 2022; 12: 805854
• 55 Bulboaca AE, Boarescu PM, Porfire AS. et al. The effect of nano-epigallocatechin-gallate on oxidative stress and matrix metalloproteinases in experimental diabetes mellitus. Antioxidants 2020; 9: 172
• 56 Mahmoud AM, Ahmed OM, Ashour MB. et al. In vivo and in vitro antidiabetic effects of citrus flavonoids; a study on the mechanism of action. Int J Diabetes Dev Ctries 2015; 35: 250-263
• 57 Alkholifi FK, Aodah AH, Foudah AI. et al. Exploring the therapeutic potential of berberine and tocopherol in managing diabetic neuropathy: A comprehensive approach towards alleviating chronic neuropathic pain. Biomedicines 2023; 11: 1726
• 58 Samarghandian S, Azimi-Nezhad M, Samini F. et al. Chrysin treatment improves diabetes and its complications in liver, brain, and pancreas in streptozotocin-induced diabetic rats. Can J Physiol Pharmacol 2016; 94: 388-393
• 59 Boonrueng P, Wasana PW, Hasriadi N. et al. Combination of curcumin and piperine synergistically improves pain-like behaviors in mouse models of pain with no potential CNS side effects. Chin Med 2022; 17: 119
• 60 Amin GS, Marouf BH, Namiq HS. et al. Impact of resveratrol and pharmaceutical care on type 2 diabetes mellitus and its neuropathic complication: A randomized placebo controlled clinical trial. J Clin Pharm Ther 2024; 2024: 7739710
• 61 Chang W, Chen L, Hatch GM. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies. Biochem Cell Biol 2015; 93: 479-486
• 62 Ali M, Hassan M, Ansari SA. et al. Quercetin and kaempferol as multi-targeting antidiabetic agents against mouse model of chemically induced type 2 diabetes. Pharmaceuticals 2024; 17: 757
• 63 Parmar M, Syed I, Gray JP. et al. Curcumin, hesperidin, and rutin selectively interfere with apoptosis signaling and attenuate streptozotocin-induced oxidative stress-mediated hyperglycemia. Current Neurovasc Res 2015; 12: 363-374
• 64 Gupta G, Siddiqui MA, Khan MM. et al. Current pharmacological trends on myricetin. Drug Res 2020; 70: 448-454
• 65 Alharbi KS, Nadeem MS, Afzal O. et al. Gingerol, a natural antioxidant, attenuates hyperglycemia and downstream complications. Metabolites 2022; 12: 1274
• 66 Hassan SS, Samanta S, Dash R. et al. The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress. Front Pharmacol 2022; 13: 1015835
• 67 Mahajan S, Sureja V, Kheni D. et al. A. Protective effects of Boswellia and Curcuma extract on oxaliplatin-induced neuropathy via modulation of NF-κB signaling. Toxicol Rep 2024; 13: 101781
• 68 Zhang ZT, Deng SM, Chen C. et al. Pterostilbene could alleviate diabetic cognitive impairment by suppressing TLR4/NF-кB pathway through microbiota-gut-brain axis. Phytother Res 2023; 37: 3522-3542
• 69 Sic A, Manzar A, Knezevic NN. The role of phytochemicals in managing neuropathic pain: How much progress have we made?. Nutrients 2024; 16: 4342
• 70 Gao J, Zhang M, Niu R. et al. The combination of cinnamaldehyde and kaempferol ameliorates glucose and lipid metabolism disorders by enhancing lipid metabolism via AMPK activation. J Funct Foods 2021; 83: 104556
• 71 Kong M, Xie K, Lv M. et al. Anti-inflammatory phytochemicals for the treatment of diabetes and its complications: Lessons learned and future promise. Biomed Pharmacother 2021; 133: 110975
• 72 Stankovic S, Mutavdzin Krneta S, Djuric D. et al. Plant polyphenols as heart’s best friends: From health properties, to cellular effects, to molecular mechanisms of action. Int J Mol Sci 2025; 26: 915
• 73 Ferraz CR, Carvalho TT, Manchope MF. et al. Mechanisms of action, pre-clinical and clinical data, and pharmaceutical development. Molecules 2020; 25: 762
• 74 Shen CL, Castro L, Fang CY. et al. Bioactive compounds for neuropathic pain: An update on preclinical studies and future perspectives. J Nutr Biochem 2022; 104: 108979
• 75 Yorek M. Combination therapy is it in the future for successfully treating peripheral diabetic neuropathy?. Front Endocrinol 2024; 15: 1357859
• 76 Rahman MM, Dhar PS, Anika F. et al. Exploring the plant-derived bioactive substances as antidiabetic agent: An extensive review. Biomed Pharmacother 2022; 152: 113217
• 77 Eghbali A, Adibifar M, Ghasemi A. et al. The effect of oral curcumin on vincristine-induced neuropathy in pediatric acute lymphoblastic leukemia: A double-blind randomized controlled clinical trial. BMC Cancer 2025; 25: 344
• 78 Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R. et al. Curcumin extract for prevention of type 2 diabetes. Diabetes Care 2012; 35: 2121-2127
• 79 Viana MD, Lauria PS, Lima AA. et al. Alpha-lipoic acid as an antioxidant strategy for managing neuropathic pain. Antioxidants 2022; 11: 2420
• 80 Abubaker SA, Alonazy AM, Abdulrahman A. Effect of alpha-lipoic acid in the treatment of diabetic neuropathy: A systematic review. Cureus 2022; 14: e25750
• 81 Vallianou N, Evangelopoulos A, Koutalas P. Alpha-lipoic acid and diabetic neuropathy. Rev Diabet Stud 2009; 6: 230-236
• 82 Han S, Yan RB, Guan S. et al. Current research progress in identifying the mechanism of berberine in pain regulation. Pharmacol Res-Mod Chin Med 2021; 1: 100019
• 83 Aryaeian N, Sedehi SK, Arablou T. Polyphenols and their effects on diabetes management: A review. Med J Islam Repub Iran 2017; 31: 134
• 84 Khodaie S-A, Nikkhah H, Namiranian N. et al. Topical Nigella sativa L. product: A new candidate for the management of diabetic peripheral neuropathy. Inflammopharmacology 2023; 2: 1-9
• 85 Wang J, Bi C, Xi H. et al. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: A systematic review and meta-analysis. Front Pharmacol 2024; 15: 1455534
• 86 Xie W, Su F, Wang G. et al. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. Front Pharmacol 2022; 13: 1015045
• 87 Santos JM, Wang R, Bhakta V. et al. Turmeric bioactive compounds alleviate spinal nerve ligation-induced neuropathic pain by suppressing glial activation and improving mitochondrial function in spinal cord and amygdala. Nutrients 2023; 15: 4403
• 88 Mijnhout GS, Alkhalaf A, Kleefstra N. et al. Alpha lipoic acid: A new treatment for neuropathic pain in patients with diabetes. Neth J Med 2010; 68: 158-162
• 89 Kim S, Cheon C, Kim B. et al. The effect of ginger and its sub-components on pain. Plants 2022; 11: 2296
• 90 Szulc-Musioł B, Sarecka-Hujar B. The use of micro-and nanocarriers for resveratrol delivery into and across the skin in different skin diseases—a literature review. Pharmaceutics 2021; 13: 451
• 91 Grover M, Shah K, Khullar G. et al. Investigation of the utility of Curcuma caesia in the treatment of diabetic neuropathy. J Pharm Pharmacol 2019; 71: 725-732
• 92 Muto N, Matsuoka Y, Arakawa K. et al. Quercetin attenuates neuropathic pain in rats with spared nerve injury. Acta Medica Okayama 2018; 72: 457-465
• 93 Hartemann A, Attal N, Bouhassira D. et al. Working Group on the Diabetic Foot from the French-speaking Society of Diabetology. Painful diabetic neuropathy: Diagnosis and management. Diabetes Metab 2011; 37: 377-388
• 94 Jahromi B, Pirvulescu I, Candido KD. et al. Herbal medicine for pain management: Efficacy and drug interactions. Pharmaceutics 2021; 13: 251
• 95 Mijnhout GS, Alkhalaf A, Kleefstra N. et al. Alpha lipoic acid: A new treatment for neuropathic pain in patients with diabetes. Neth J Med 2010; 68: 158-162
• 96 Grover M, Shah K, Khullar G. et al. Investigation of the utility of Curcuma caesia in the treatment of diabetic neuropathy. J Pharm Pharmacol 2019; 71: 725-732
• 97 Antony B, Merina B, Iyer VS. et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95® CG (Biocurcumax™), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci 2008; 70: 445
• 98 Sunagawa Y, Hirano S, Katanasaka Y. et al. Colloidal submicron-particle curcumin exhibits high absorption efficiency—a double-blind, 3-way crossover study. J Nutr Sci Vitaminol 2015; 61: 37-44
• 99 Shoba G, Joy D, Joseph T. et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica 1998; 64: 353-356
• 100 Purpura M, Lowery RP, Wilson JM. et al. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects. Eur J Nutr 2018; 57: 929-938
• 101 Hegde M, Girisa S, Bharathwaj Chetty B. et al. Curcumin formulations for better bioavailability: What we learned from clinical trials thus far?. ACS Omega 2023; 8: 10713-10746
• 102 Hu Y, Lin Q, Zhao H. et al. Bioaccessibility and bioavailability of phytochemicals: Influencing factors, improvements, and evaluations. Food Hydrocolloids 2023; 135: 108165
• 103 Talebi M, Shahbazi K, Dakkali MS. et al. Phytosomes: A promising nanocarrier system for enhanced bioavailability and therapeutic efficacy of herbal products. Phytomedicine Plus. 2025: 1-16 100779
• 104 Dewanjee S, Chakraborty P, Mukherjee B. et al. Plant-based antidiabetic nanoformulations: The emerging paradigm for effective therapy. Int J Mol Sci 2020; 21: 2217
• 105 Attia M, Essa EA, Zaki RM. et al. An overview of the antioxidant effects of ascorbic acid and alpha lipoic acid (in liposomal forms) as adjuvant in cancer treatment. Antioxidants 2020; 9: 359